Trump's Tariff Tactics: A Prescription for Pharmaceutical Production

President Donald Trump has signed an executive mandate imposing steep tariffs on imported branded pharmaceuticals into the United States. The intent is clear: compel drug manufacturers to either adhere to government-set pricing agreements or relocate production to domestic shores. The overarching goal is to reign in soaring prescription drug prices.

The executive order stipulates a 100% tariff on patented drugs not manufactured domestically nor covered under drug pricing agreements. Pharmaceutical giants have a 120-day timeframe to announce plans to sidestep this tariff, whereas smaller firms have 180 days. By moving manufacturing to the U.S., companies can benefit from a significantly reduced 20% tariff.

Exemptions have been outlined for drugmakers agreeing to onshore production and signing most-favored-nation pricing agreements. Such arrangements have already been finalized with several companies. Special considerations are also in place for generic drugs, ensuring they remain tariff-free for at least a year, benefitting over 90% of the U.S. medication market.